SCHEMBL1147804

SCHEMBL1147804

CC(NC(=O)c1cc(Cl)ccc1NC(=O)C1CC(c2cc([N+](=O)[O-])ccc2S(=O)(=O)O)=NN1c1ncccc1Cl)C1CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.34
F10 P00742 1/20 0.34
KMT2A Q03164 4/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
HTT P42858 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 4/20 0.32
MAPT P10636 3/20 0.32
MEN1 O00255 3/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
AURKA O14965 1/20 0.32
PDPK1 O15530 1/20 0.32
JAK2 O60674 1/20 0.32
GMNN O75496 1/20 0.32
EGFR P00533 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15085584 0.91 F10 (0.36) F10NPC1RAB9ATP53MALT1
SCHEMBL15085562 0.90 MALT1 (0.34) ALDH1A1KMT2ANPC1RAB9AHTT
SCHEMBL15085595 0.90 F10 (0.34) ALDH1A1F10KMT2ANPC1RAB9A
SCHEMBL15085530 0.90 ALDH1A1 (0.33) ALDH1A1KMT2ANPC1RAB9AHTT
SCHEMBL15085565 0.89 F10 (0.34) ALDH1A1F10KMT2ANPC1RAB9A
SCHEMBL15085578 0.87 CNR2 (0.35) ALDH1A1F10KMT2ANPC1RAB9A
SCHEMBL15085552 0.87 F10 (0.37) F10NPC1RAB9AHTTTP53
SCHEMBL15085594 0.86 F10 (0.37) F10NPC1RAB9AHTTMALT1
SCHEMBL1148408 0.85 F10 (0.36) ALDH1A1F10KMT2ANPC1RAB9A
SCHEMBL1147738 0.83 GPR17 (0.37) F10KMT2AHTTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481744-B2 Process for producing anthranilamide compound ISHIHARA SANGYO KAISHA, LTD. (JP) 2013-07-09 US disclosed
US-20110034696-A1 PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA, LTD. (JP) 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034696-A1 PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND SQOR, NOX5, NOX3 ALDH1A1 819/4885F10 934/4885KMT2A 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.